BCYP SEC filings, in plain English
Everything Big Cypress Acquisition Corp. has filed with the SEC that we hold — 40 filings, newest first, 3 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: SAB Biotherapeutics filed its Q2 2026 10-Q showing 90,986,368 shares outstanding as of August 3, 2026, up from 47,664,564 at year-end 2025, driven by a March 2026 public offering (~21.9M shares at $3.85/share for ~$88.7M net) and Series B preferred conversions. Net loss widened to $41.4M for the six months ended June 30, 2026 (vs. $15.3M in 1H 2025), with R&D spending nearly doubling to $29.6M as the Phase 2b SAFEGUARD trial for SAB-142 progressed. Why it matters: The company is burning cash faster as it advances its registrational Phase 2b trial, with operating cash usage of $24.1M in 1H 2026, but states existing resources are sufficient for at least 12 months. The March 2026 raise extended runway, but the accumulated deficit reached $152.3M and further dilution or capital raises will likely be needed to fund commercial readiness.
What changed: SAB Biotherapeutics, Inc., the Big Cypress Acquisition Corp. successor, furnished a July 7, 2026 press release issued with Breakthrough T1D announcing that the organisation has awarded a grant to Michael J. Haller, M.D., Professor and Chief of Pediatric Endocrinology at the University of Florida, in support of PRISE-hATG. That clinical study evaluates SAB-142 in patients with Stage 3 type 1 diabetes who are 100 days to two years from diagnosis, Stage 3 being the point at which insulin is required. The information is furnished rather than filed. Why it matters: Third-party grant funding for a study of the company's lead asset shifts part of the clinical development cost off its own balance sheet, which is meaningful for a de-SPAC funding trials from a finite cash balance. It also carries an implicit endorsement from the principal type 1 diabetes research organisation. The study population is narrow — patients within two years of a Stage 3 diagnosis — so a positive result would support a specific label rather than the broader indication the equity story assumes.
What changed: SAB Biotherapeutics, Inc. (successor to SPAC Big Cypress Acquisition Corp) called its 2026 annual meeting for Thursday, June 18, 2026 at 10:00 a.m. ET at virtualshareholdermeeting.com/SABS2026, exclusively online with no physical meeting, record date April 20, 2026. Holders elect Katie Ellias, David Link and Andrew Moin as Class II directors for three-year terms and ratify EisnerAmper LLP as auditor for the fiscal year ending December 31, 2026. Series A Preferred outstanding on the record date is generally entitled to vote alongside common. Why it matters: Routine annual governance with no trust, extension or redemption mechanics left from the Big Cypress SPAC. The one structural item for common holders is that Series A Preferred votes generally alongside common stock, so a preferred block that ranks ahead of common in liquidation also carries voting power on director elections and any future proposals, diluting the influence of the public float. A staggered board with three-year Class II terms further limits how quickly shareholders could change board composition.
- What changed vs 2025-03-31going concern RESOLVED
going-concern doubt, mandate language1 moved · 1 with no prior record of ours
- Going-concern doubt
- statednot stated
- Mandate language
- We intend to pursue agreements with contract manufacturers t… · unchanged
SpacBrain reads this as the substantial-doubt sentence is in the previous filing and not in this one.
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.